•
Jun 30, 2022
Agenus Q2 2022 Earnings Report
Agenus reported financial results for the second quarter of 2022.
Key Takeaways
Agenus reported a revenue of $21 million for the second quarter ended June 30, 2022, representing an increase of $10 million from the same period in 2021. The net loss for the quarter was $49 million or $0.17 per share, compared to a net loss of $84 million or $0.37 per share for the quarter ended June 30, 2021.
Agenus presented botensilimab/balstilimab combination data in MSS colorectal cancer at ESMO GI.
Botensilimab/balstilimab data to drive rapid enrollment in randomized trials
Clinical-stage pipeline continues to advance
Company ends Q2 in a strong financial position
Agenus
Agenus
Forward Guidance
This report does not contain any forward guidance.